Ticagrelor
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ticagrelor: From Acute Coronary Syndrome to Intracranial Arteriosclerosis
One-Sentence Summary
Ticagrelor is a P2Y12 platelet inhibitor originally used for the prevention of atherothrombotic events in acute coronary syndrome (ACS). The TxGNN model predicts it may also be effective for Intracranial Arteriosclerosis, with 11 clinical trials and 3 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute Coronary Syndrome (ACS) / secondary prevention of atherothrombotic events — established global indication; specific German label text not available in this evidence pack |
| Predicted New Indication | Intracranial Arteriosclerosis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on publicly established pharmacology, ticagrelor is a reversible, direct-acting oral P2Y12 receptor antagonist that inhibits ADP-induced platelet aggregation, and additionally increases local adenosine concentration by inhibiting equilibrative nucleoside transporter 1 (ENT-1) — a mechanism proposed to confer pleiotropic vascular benefits beyond antiplatelet activity.
Acute coronary syndrome and intracranial arteriosclerosis (intracranial atherosclerotic disease, ICAD) share the same underlying pathophysiology: atherosclerotic plaque formation and platelet-mediated thrombus formation leading to vessel occlusion. Since ticagrelor's efficacy in reducing atherothrombotic events in ACS and peripheral artery disease is well established (e.g., PLATO, EUCLID, THEMIS), extension of the P2Y12 inhibition mechanism to intracranial vessels is mechanistically plausible.
This is further supported by the fact that ticagrelor is already being actively investigated as an alternative to clopidogrel for symptomatic intracranial atherosclerotic stenosis, most notably in the dedicated CAPTIVA trial, which directly compares ticagrelor- and rivaroxaban-based regimens against clopidogrel for lowering 1-year rates of ischemic stroke, intracerebral hemorrhage, or vascular death in this population.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05047172 | Phase 3 | Active, not recruiting | 1,683 | CAPTIVA — determines whether rivaroxaban, ticagrelor, or both are superior to clopidogrel in lowering 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death in intracranial vascular atherostenosis |
| NCT06714526 | N/A | Recruiting | 100 | Pilot RCT of genotype-guided P2Y12 inhibitor selection (incl. ticagrelor) vs. conventional clopidogrel in symptomatic intracranial atherosclerotic disease (ICAD) |
| NCT04948749 | N/A | Recruiting | 792 | DREAM-PRIDE — drug-eluting stent + aggressive medical treatment (including antiplatelet therapy) vs. standard medical treatment for preventing recurrent stroke in symptomatic ICAD |
| NCT06058130 | N/A | Unknown | 2,171 | Anticoagulation vs. anticoagulation + antiplatelet therapy in acute ischemic stroke with concomitant atrial fibrillation and extracranial/intracranial artery stenosis |
| NCT01813435 | Phase 3 | Completed | 15,991 | GLOBAL LEADERS — ticagrelor + aspirin (1 month) then ticagrelor monotherapy (23 months) vs. standard DAPT after stent implantation |
| NCT01732822 | Phase 3 | Completed | 13,885 | EUCLID — ticagrelor vs. clopidogrel for reducing CV death, MI, and ischemic stroke in peripheral artery disease |
| NCT06857045 | N/A | Withdrawn | 0 | 3- vs. 6-month DAPT after NOVA intracranial sirolimus-eluting stent implantation |
| NCT02605447 | Phase 4 | Completed | 2,009 | EVOLVE Short DAPT — safety of 3-month DAPT in high bleeding-risk patients undergoing PCI |
| NCT03620760 | Phase 4 | Unknown | 2,036 | Low-dose (45mg BID) vs. standard-dose (90mg BID) ticagrelor after drug-eluting stent implantation in unstable angina |
| NCT07164859 | Phase 3 | Not yet recruiting | 1,700 | SOLOPCI — very short DAPT followed by P2Y12 monotherapy in elderly PCI patients (≥65 years) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39862061 | 2025 | Trial Protocol | International Journal of Stroke | Describes design/early progress of CAPTIVA, testing whether alternative dual antithrombotic combinations (including ticagrelor) outperform standard clopidogrel + aspirin for symptomatic ICAS |
| 38252758 | 2024 | Review | Stroke | Focused update on intracranial atherosclerosis — introduction, highlights, and knowledge gaps in current antithrombotic management |
| 39658130 | 2025 | Retrospective Cohort | Journal of NeuroInterventional Surgery | Compares lower-dose ticagrelor (60mg BID) + aspirin vs. standard aspirin + clopidogrel for neurointerventional/intracranial stenting procedures |
Germany Market Information
Ticagrelor is currently not marketed in Germany under this evidence pack's data source, and no authorization records (Zulassungsnummer) are available for listing.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale and supporting Phase 3 evidence (GLOBAL LEADERS, EUCLID) for ticagrelor's antiplatelet effect in atherosclerotic vascular disease are strong, and a dedicated Phase 3 RCT (CAPTIVA) specific to intracranial arteriosclerosis is actively underway. However, safety label data (warnings, contraindications, DDI) is a blocking data gap, and ticagrelor currently has zero authorizations in the German market, preventing a complete safety and regulatory assessment.
To proceed, the following is needed:
- Obtain the German/EU Fachinformation (SmPC) for ticagrelor to complete S1 safety review (warnings, contraindications, DDI — particularly known strong CYP3A4 interactions)
- Confirm the original approved indication text and detailed mechanism of action (MOA) from DrugBank or regulatory source
- Monitor CAPTIVA trial completion (expected 2027) for direct disease-specific efficacy/safety readout in intracranial arteriosclerosis
- Assess local pathway for market entry given current "not marketed" status in Germany
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.